Status:
COMPLETED
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are n...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening
- HbA1c \>or = 7% and \< or = 10%
- Fasting c-peptide \> or = 1.0 umol
- Body Mass Index \< or = 41 kg/m2
- Mean serum triglycerides \< or = 600 mg/dl
Exclusion
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
1752 Patients enrolled
Trial Details
Trial ID
NCT00095030
Start Date
February 1 2004
End Date
March 1 2006
Last Update
September 14 2010
Active Locations (206)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Birmingham, Alabama, United States
2
Local Institution
Mesa, Arizona, United States
3
Local Institution
Phoenix, Arizona, United States
4
Local Institution
Tucson, Arizona, United States